SCHEMBL1991595

SCHEMBL1991595

COc1ccc(Cl)cc1-c1ccc(S(=O)(=O)c2ccc(F)cc2)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.47
PGR P06401 1/20 0.47
PTGS2 P35354 8/20 0.46
PTGS1 P23219 4/20 0.46
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NR1I2 O75469 3/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
PTGES2 Q9H7Z7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1989561 0.87 NR3C1 (0.53) NR3C1PGRPTGS2PTGS1POLB
SCHEMBL2908208 0.87 PTGS2 (0.47) PTGS2PTGS1SMN1; SMN2NR1I2
SCHEMBL1989553 0.83 HTR6 (0.51) NR3C1PGRPTGS2PTGS1SMN1; SMN2
SCHEMBL1988963 0.82 PTGDR2 (0.60) PTGDR2
SCHEMBL1993521 0.81 POLB (0.46) PTGS2PTGS1POLBPTGDR2
SCHEMBL14828506 0.81 PTGDR2 (0.43) PTGDR2
SCHEMBL1989562 0.80 PTGS2 (0.45) NR3C1PGRPTGS2PTGS1
SCHEMBL1994155 0.79 PTGDR2 (0.51) NR3C1PGRPTGS2PTGS1TP53
SCHEMBL3435294 0.79 NR1I2 (0.45) NR3C1PGRTP53POLBSMN1; SMN2
SCHEMBL1998315 0.78 NR3C1 (0.49) NR3C1PGRPTGS2PTGS1PTGES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415394-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (GB) 2013-04-09 US disclosed
US-8349897-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2013-01-08 US disclosed
US-20120178814-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease LUKER TIMOTHY JON (GB) 2012-07-12 US disclosed
US-8008350-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2011-08-30 US disclosed
US-20110152374-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2011-06-23 US disclosed
EP-1937633-B8 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2010-12-22 EP disclosed
EP-1937633-B1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2010-08-04 EP disclosed
US-20090036535-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2009-02-05 US disclosed
EP-1937633-A1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE Astra Zeneca AB (SE) 2008-07-02 EP disclosed
WO-2007039741-A1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178814-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease BPGM, PPARA, HPD NR3C1 619/4885PGR 1925/4885PTGS2 1220/4885
US-20110152374-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease BPGM, PPARA, HPD NR3C1 619/4885PGR 1925/4885PTGS2 1220/4885
US-20090036535-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease BPGM, PPARA, HPD NR3C1 619/4885PGR 1925/4885PTGS2 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.